RxDoctor Payments Data

Elias Ugwu, MD

Nephrology · North Las Vegas, NVNPI 1942546296

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,726 of the $1,912 with a category attached, or 90.3%. Boehringer Ingelheim accounts for 90.7% of it on its own, with 3 other manufacturers making up the rest. 2022 is the largest year on record at $1,734, more than ten times the $122 reported in 2019.

$1,912in general payments, 2019–2025

Across 8 payments — averaging $238.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • Otsuka America Pharmaceutical, Inc.$122
  • AbbVie$36
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$20
$128,261in research payments, 2019–2025

Across 21 payments — averaging $6107.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim International GmbH$79K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$49K

What the payments were for

  • Travel & lodging$1,72690%
  • Food & beverage$18610%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,912 in reported general payments places this provider in the 55th percentile of 125 nephrology providers in Nevada.

See all nephrology providers in Nevada

Medicare billing

Part B allowed, 2024
$9,525
Medicare patients
52
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in North Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →